Latest news
A new Lp(a) threshold could reshape cardiovascular risk assessment
Researchers have identified a lipoprotein(a) level above 175 nmol/L as a marker of substantially increased cardiovascular risk, strengthening the case for routine testing and future use of emerging Lp(a)-lowering therapies.
Regulators Start Writing the Rules for AI-Driven Medicines
AI Pathology Moves From Demo to Workflow
FDA Puts AI Inside the Evidence Machine
AlphaGenome Makes Variant Interpretation Political
AI Diagnosis Has Entered the Access Debate
The AMR Pipeline Is Too Thin for the Threat Ahead
TB Diagnosis Moves Closer to the Patient
Hepatitis Elimination Is Still Losing Patients Before Diagnosis
Lenacapavir Turns HIV Prevention Into an Access Stress Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.